Heteroclitic immunization induces tumor immunity

Journal of Experimental Medicine

Volumn 188, Issue 9, 1998, Pages 1553-1561

  Dyall, Ruben ^a   Bowne, Wilbur B ^a   Weber, Lawrence W ^a   LeMaoult, Joel ^a   Szabo, Paul ^b   Moroi, Yoichi ^a   Piskun, Gregory ^a   Lewis, Jonathan J ^a   Houghton, Alan N ^a   Nikolić Žugić, Janko ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cytotoxic T lymphocyte; Heteroclitic peptides; Major histocompatibility complex class I; Peptide vaccines; Tumors

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNIZATION; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; VACCINATION;

EID: 18144437002     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.9.1553     Document Type: Article

References (33)

1. Houghton, A.N. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1-4.
2. Bretscher, P., and M. Cohn. 1970. A theory of self-nonself discrimination. Science. 169:1042-1049.
3. Jenkins, M.K., J.D. Ashwell, and R.H. Schwartz. 1988. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J. Immunol. 140:3324-3330.
4. Schwartz, R.H. 1990. A cell culture model for T lymphocyte clonal anergy. Science. 248:1349-1356.
5. Nossal, G.V.J. 1994. Negative selection of lymphocytes. Cell. 76:229-240.
6. Vukmanović, S., M.J. Bevan, and K.A. Hogquist. 1993. The specificity of positive selection: MHC and peptides. Immunol. Rev. 135:51-66.
7. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W.M. Kast, C.J.M. Melief, C. Oseroff, L. Yuan, J. Ruppert, et al. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586-5597.
8. Robbins, P.F., and Y. Kawakami. 1996. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8:628-636.
9. Solinger, A.M, M.E. Ultee, E. Margoliash, and R.H. Schwartz. 1979. T-lymphocyte response to cytochrome c. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histocompatibility complex-linked immune response genes. J. Exp. Med. 150:830-848.
10. Madden, D.R. 1995. The three dimensional structure of peptide-MHC complexes. Annu. Rev. Immunol. 13:587-622.
11. Garcia, C.G., M. Degano, R.L. Stanfield, A. Brunmark, M.R. Jackson, P.A. Peterson, L. Teyton, and I.A. Wilson. 1996. An αβ T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science. 274:209-216.
12. Garboczi, D.N., P. Ghosh, U. Utz, Q.R. Fan, W.E. Biddison, and D.C. Wiley. 1996. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature. 384:134-141.
13. Boehncke, W.H., T. Takeshita, C.D. Pendleton, R.C. Houghten, S. Sadegh-Nasseri, L. Racioppi, J.A. Berzofsky, and R.N. Germain. 1993. The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition. J. Immunol. 150:331-339.
14. England, R.D., M.C. Killberg, J.L. Conette, and J.A. Berzofsky. 1995. Molecular analysis of a heteroclitic T cell response to the immunodominant epitope of sperm whale myoglobin. Implications for peptide partial agonists. J. Immunol. 155: 4295-4306.
15. van der Burg, S.H., M.J. Visseren, R.M. Brandt, W.M. Kast, and C.J. Melief. 1996. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156:3308-3314.
16. Dyall, R., D.H. Fremont, S.C. Jameson, and J. Nikolić-Žugić. 1996. T cell receptor (TCR) recognition of MHC Class I variants: intermolecular second-site reversion provides evidence for peptide/MHC conformational variation. J. Exp. Med. 184:253-258.
17. Yewdell, J., C. Lapham, I. Bacik, T. Spies, and J. Bennink. 1994. MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation. J. Immunol. 152:1163-1170.
18. Anderson, K., P. Cresswell, M. Gammon, J. Hermes, A. Williamson, and H. Zweerink. 1991. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J. Exp. Med. 174:489-492.
19. Dyall, R., L.V. Vasović, A. Molano, and J. Nikolić-Žugić. 1995. CD4-independent priming of murine CTLs by optimal MHC class I-restricted peptides in vivo. Int. Immunol. 7: 1205-1212.
20. Ross, H., L.W. Weber, S. Wang, Y. Takechi, G. Piskun, R. Dyall, J. Nikolić-Žugić, A.N. Houghton, and J.J. Lewis. 1997. Priming for T cell mediated rejection of tumors by cutaneous DNA immunization. Clin. Cancer Res. 3:2191-2196.
21. Ljunggren, H.G., and K. Karre. 1985. Host resistance directed selectively against H-2 deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med. 162:1745-1759.
22. Vijayasaradhi, S., B. Bouchard, and A.N. Houghton. 1990. The melanoma antigen gp75 is the human homologue of the mouse b (Brown) locus gene product. J. Exp. Med. 171:1375-1380.
23. Houghton, A.N., S. Vijayasaradhi, B. Bouchard, C. Naftzger, I. Hara, and P.B. Chapman. 1993. Recognition of autoantigens by patients with melanoma. Ann. NY Acad. Sci. 690:59-68.
24. Wang, R.F., E. Appella, Y. Kawakami, X. Kang, and S.A. Rosenberg. 1996. Identification of TRP2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184:2207-2216.
25. Hara, I., Y. Takechi, and A.N. Houghton. 1995. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the BROWN locus protein. J. Exp. Med. 182:1609-1614.
26. Naftzger, C., Y. Takechi, H. Kohda, I. Hara, S. Vijayasaradhi, and A.N. Houghton. 1996. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA. 93:14809-14814.
27. Rammensee, H.-G., K. Falk, and O. Rotzschke. 1993. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11:213-244.
28. Shibahara, S., Y. Tomita, T. Sakakura, C. Nager, B. Chaudhuri, and R. Muller. 1986. Cloning and expression of cDNA encoding mouse tyrosinase. Nucleic Acids Res. 14: 2413-2427.
29. Takechi, Y., I. Hara, C. Naftzger, Y. Xu, and A.N. Houghton. 1996. A melanosomal protein is a cell surface target for melanoma therapy. Clin. Cancer Res. 2:1837-1842.
30. Lipford, G.B., S. Bauer, H. Wagner, and K. Heeg. 1995. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumor antigen, E6. Immunology. 84:298-303.
31. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183:1965-1971.
32. Bakker, A.B.H., S.H. van der Burg, R.J. Huijbens, J.-W. Drijfhout, C.J.M. Melief, G.J. Adema, and C.G. Figdor. 1997. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type tumor epitope. Int. J. Cancer. 70:302-309.
33. Overwijk, W.W., A. Tsung, K.R. Irvine, M.R. Parkhurst, T.J. Goletz, K. Tsung, M.W. Carroll, C. Liu, B. Moss, S.A. Rosenberg, and N.P. Restifo. 1998. gp 100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-286.